Advice
Following a full submission:
olanzapine (Zyprexa) is accepted for use within NHS Scotland for the prevention of recurrence in patients with bipolar disorder whose manic episode has responded to olanzapine treatment.
Olanzapine has been shown to be significantly superior to placebo in delaying symptomatic relapse of mania or depression and of mania alone. Apart from weight gain, somnolence and treatment-emergent depression, most significant differences between olanzapine and active competitors favoured olanzapine.
Download detailed advice21KB (PDF)
Medicine details
- Medicine name:
- Olanzapine (Zyprexa)
- SMC ID:
- 98/04
- Indication:
- for prevention of recurrence in bipolar disorder
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 10 May 2004